<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[36, 43] patients with atrial fibrillation (AF)<br>[153, 164] 18,113 patients. Patients who were VKA-naive and experienced<br></td>
<td width=33%>
[36, 43] patients with atrial fibrillation (AF)<br>[127, 147] multinational (44 countries) trial of patients with nonvalvular AF and at least 1 risk factor for stroke.<br>[153, 156] 18,113 patients.<br>[156, 164] Patients who were VKA-naive and experienced<br></td>
<td width=33%>
[36, 43] patients with atrial fibrillation (AF)<br>[116, 147] a phase 3, prospective, randomized, open-label multinational (44 countries) trial of patients with nonvalvular AF and at least 1 risk factor for stroke.<br>[149, 156] with a total of 18,113 patients.<br>[156, 170] Patients who were VKA-naive and experienced are included in balanced proportions.<br></td>
</tr>
